PB 101 of 2025
National Health (Minimum Stockholding) Amendment Determination (No. 8) 2025
I, Rebecca Richardson, as delegate of the Minister for Health and Ageing, make the following determination.
Dated 25 August 2025
Rebecca Richardson
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing
1 Name
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments commencing 1 September 2025
National Health (Minimum Stockholding) Determination 2023
Schedule 2—Amendments commencing 1 October 2025
National Health (Minimum Stockholding) Determination 2023
(1) This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 8) 2025.
(2) This instrument may also be cited as PB 101 of 2025.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 September 2025. | 1 September 2025 |
2. Schedule 1 | 1 September 2025. | 1 September 2025 |
3. Schedule 2 | 1 October 2025. | 1 October 2025 |
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under subsection 99AEKC(2) of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
1 Schedule 1 (table)
Omit:
Aciclovir | Tablet 800 mg | Oral | Aciclovir APOTEX | 4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together |
2 Schedule 1 (table)
Omit:
Amisulpride | Tablet 400 mg | Oral | Amipride 400 | between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand |
3 Schedule 1 (table)
Omit:
Celecoxib | Capsule 100 mg | Oral | Blooms the Chemist Celecoxib | between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand |
4 Schedule 1 (table)
Omit:
Fentanyl | Transdermal patch 1.28 mg | Transdermal | Denpax | between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand |
Fentanyl | Transdermal patch 10.20 mg | Transdermal | Denpax | between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand |
Fentanyl | Transdermal patch 12.375 mg | Transdermal | Fenpatch 75 | between 1 August 2025 and 31 August 2025—0 months stock by reference to usual demand |
5 Schedule 1 (table)
Omit:
Fentanyl | Transdermal patch 2.063 mg | Transdermal | Fenpatch 12 | between 1 August 2025 and 31 August 2025—0 months stock by reference to usual demand |
6 Schedule 1 (table)
Omit:
Fentanyl | Transdermal patch 2.55 mg | Transdermal | Denpax | between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand |
7 Schedule 1 (table)
Omit:
Fentanyl | Transdermal patch 5.10 mg | Transdermal | Denpax | between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand |
Fentanyl | Transdermal patch 7.65 mg | Transdermal | Denpax | between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand |
8 Schedule 1 (table)
Omit:
Insect allergen extract‑yellow jacket venom | Injection set containing 550 micrograms with diluent | Injection | Hymenoptera Yellow Jacket Venom | 6 months stock by reference to usual PBS demand |
substitute:
Insect allergen extract-yellow jacket venom | Injection set containing 550 micrograms | Injection | Albey Yellow Jacket Venom | 6 months stock by reference to usual PBS demand of Insect allergen extract-yellow jacket venom, Injection set containing 550 micrograms with diluent, Injection (Hymenoptera Yellow Jacket Venom) and Insect allergen extract-yellow jacket venom, Injection set containing 550 micrograms, Injection (Albey Yellow Jacket Venom) |
9 Schedule 1 (table)
Omit:
Irbesartan with hydrochlorothiazide | Tablet 150 mg-12.5 mg | Oral | Blooms the Chemist Irbesartan HCTZ 150/12.5 | between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand |
Irbesartan with hydrochlorothiazide | Tablet 300 mg-12.5 mg | Oral | Blooms the Chemist Irbesartan HCTZ 300/12.5 | between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand |
10 Schedule 1 (table)
After:
Modafinil | Tablet 100 mg | Oral | Modafinil Viatris | after 28 February 2025— 4 months stock by reference to usual demand of both Modafinil Viatris and Modafinil Mylan added together |
insert:
Mometasone | Ointment containing mometasone furoate 1 mg per g, 15 g | Application | Momasone | between 1 September 2025 to 28 February 2026—0 months stock by reference to usual demand |
11 Schedule 1 (table)
Omit:
Olanzapine | Tablet 10 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 10 mg (orally disintegrating), Oral, added together |
12 Schedule 1 (table)
Omit:
Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 15 mg (orally disintegrating), Oral, added together. |
13 Schedule 1 (table)
Omit:
Olanzapine | Tablet 20 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 20 mg (orally disintegrating), Oral, added together |
14 Schedule 1 (table)
Omit:
Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | Zypine ODT | (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 5 mg (orally disintegrating), Oral, added together |
15 Schedule 1 (table)
Omit:
Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Tenofovir APOTEX | 4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together |
16 Schedule 1 (table)
Omit:
Vinorelbine | Solution for I.V. infusion 50 mg (as tartrate) in 5 mL | Injection | Navelbine | between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand |
1 Schedule 1 (table)
Omit:
Budesonide | Nebuliser suspension 500 micrograms in 2 mL single dose units, 30 | Inhalation | Pulmicort Respules | 6 months stock by reference to usual PBS demand |
substitute:
Budesonide | Nebuliser suspension 500 micrograms in 2 mL single dose units, 30 | Inhalation | Pulmicort Respules | (a) between 1 October 2025 and 31 March 2026—7,770 packs of a pack quantity of 1 (b) after 31 March 2026—6 months stock by reference to usual PBS demand |
2 Schedule 1 (table)
Omit:
Budesonide | Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses | Inhalation by Mouth | Pulmicort Turbuhaler | 6 months stock by reference to usual PBS demand |
substitute:
Budesonide | Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses | Inhalation by Mouth | Pulmicort Turbuhaler | (a) between 1 October 2025 and 31 March 2026—31,080 packs of a pack quantity of 1 (b) after 31 March 2026—6 months stock by reference to usual PBS demand |
3 Schedule 1 (table)
Omit:
Ondansetron | Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL | Oral | Zofran syrup 50 mL | 4 months stock by reference to usual PBS demand |
substitute:
Ondansetron | Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL | Oral | Zofran syrup 50 mL | (a) between 1 October 2025 and 31 March 2026—2,204 packs of a pack quantity of 1 (b) after 31 March 2026—4 months stock by reference to usual PBS demand |
4 Schedule 1 (table)
Omit:
Permethrin | Cream 50 mg per g, 30 g | Application | Lyclear | 6 months stock by reference to usual PBS demand |
substitute:
Permethrin | Cream 50 mg per g, 30 g | Application | Lyclear | (a) between 1 October 2025 and 31 March 2026—25,734 packs of a pack quantity of 1 (b) after 31 March 2026—6 months stock by reference to usual PBS demand |